Although BCMA-directed CAR-T cells therapy has shown high objective response rates in the treatment of RRMM patients, its efficacy is not promising for patients with low or negative BCMA expression, and most patients still experience resistance and progression, which led to the exploration of alternative targets for the treatment of MM. Here, TNFRSF17 is linked to Miyoshi myopathy.